MTVA News

(RTTNews) - MetaVia Inc. (MTVA), a clinical-stage biotechnology company, on Tuesday announced the appointment of Sarah Browne as Chief Medical Officer, effective October 12...

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical OfficerPR NewswireCAMBRIDGE, Mass., Oct. 13, 2026Brings Extensive Experience Leading Liver and...

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction PR Newswire CAMBRIDGE, Mass., Sept. 9, 2026 Tissue Distribution Study...

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., Aug. 6, 2026 All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg...

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., July 9, 2026 All Active Patients in Both...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum PR Newswire CAMBRIDGE, Mass., June 17, 2026 CAMBRIDGE, Mass., June 17, 2026...

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726...

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR Newswire CAMBRIDGE, Mass., June 4, 2026 CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ --MetaVia Inc...